Leveraging cutting-edge
scientific research and technology
Leveraging cutting-edge
scientific research and technology
Who we are
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders.
Our mission
We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
Our approach
By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.
YPO Psychedelic Medicine for Mental Health Group – A Conversation with Christian Angermayer
Join Richard Simon, Chair at YPO (Young Presidents Organization) Psychedelic Medicines for Mental Health Group,
Mental health in a time of COVID-19
Whether you’re on lockdown or just practicing social distancing, chances are you’re beginning to feel
EntheogeniX Biosciences gets going
Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy
Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience
Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses,
YPO Psychedelic Medicine for Mental Health Group – A Conversation with Christian Angermayer
Join Richard Simon, Chair at YPO (Young Presidents Organization) Psychedelic Medicines for Mental Health Group,
Psychedelic Drugs Can Improve Quality Of Life – And Death – For Older Adults
Compass Pathway’s recent raise of $80M to expand research into the clinical uses of psilocybin only affirms that no coronavirus is going to dampen efforts to make these treatments legal and widely accessible.
Biotech startup wants to make new short-acting psychedelic drugs more scalable & accessible
Born out of the desire to create psychedelic compounds more scalable than psilocybin, biotech startup EntheogeniX wants to make new, short-acting drugs that are “pharmacologically cleaner” than magic mushrooms, so more patients and practitioners can benefit from their use.
Thiel Capital’s Jason Camm Discusses Joining Psychedelics Company ATAI Following $24 Million Raise
A couple days ago, ATAI Life Sciences, a biotech company developing psychedelic medicines for a variety of mental health indication, announced that it had raised $24 million in a convertible note financing round.
Thiel Backs Psychedelic-Drug Startup in Latest Funding Round
Billionaire investor Peter Thiel made his first investment in ATAI Life Sciences, a German startup that’s looking into ways of using magic mushrooms and other psychedelics to treat mental-health disorders.
Psychedelic Drugs Can Improve Quality Of Life – And Death – For Older Adults
Compass Pathway’s recent raise of $80M to expand research into the clinical uses of psilocybin only affirms that no coronavirus is going to dampen efforts to make these treatments legal and widely accessible.
Vast experience
and great access to deal flow
Vast experience
and great access to deal flow
Work with us
to improve the lives of millions of people
Work with us
to improve the lives of millions of people
WE ARE HIRING! Learn about career opportunities at ATAI and see open jobs across our platform companies.
Join the ATAI #InsightNetwork
Join the ATAI #InsightNetwork
Sign up below to receive the latest news on ATAI and innovations in the biotech and mental healthcare space